Researchers at Mayo Clinic have found that the experimental drug they are testing to treat a deadly form of thyroid cancer turns on a powerful tumor suppressor capable of halting cell growth. Few other cancer drugs have this property, they say.
Get the full story...
Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States, President: Shigeru Kobayashi), its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.
Get the full story...
Cancer research and drug development are yielding more sophisticated candidate therapies, but investigators' methods to test them haven't kept pace, according to researchers at Memorial Sloan-Kettering Cancer Center. That could explain why so many experimental drugs fail in the final large and costly phase of testing, they say.
Read the full story
A test developed by Dana-Farber Cancer Institute scientists is the first to identify which malignant blood cells are highly vulnerable to a promising type of experimental drugs that unleash pent-up "cell suicide" factors to destroy the cancer.
Read the full story
